Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Expected to Rise, HC Wainwright Analyst Says

Collegium Pharmaceutical (NASDAQ:COLL) had its price target boosted by equities research analysts at HC Wainwright from $44.00 to $46.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 13.13% from the company’s current price.

COLL has been the subject of several other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Hold” and a consensus target price of $43.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $40.66 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical has a 52 week low of $23.23 and a 52 week high of $41.81. The firm has a 50 day moving average of $35.63 and a 200-day moving average of $32.65. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 39.10 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. The business had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. On average, equities analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director Gino Santini sold 5,405 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $37.19, for a total value of $201,011.95. Following the completion of the transaction, the director owned 95,042 shares in the company, valued at $3,534,611.98. This represents a 5.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $38.21, for a total transaction of $626,223.69. Following the completion of the transaction, the executive vice president directly owned 103,613 shares in the company, valued at $3,959,052.73. This trade represents a 13.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 44,133 shares of company stock valued at $1,683,604. Insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC purchased a new stake in Collegium Pharmaceutical in the first quarter worth $244,000. Envestnet Asset Management Inc. grew its stake in shares of Collegium Pharmaceutical by 26.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 30,892 shares of the specialty pharmaceutical company’s stock worth $922,000 after acquiring an additional 6,554 shares during the period. Emerald Mutual Fund Advisers Trust increased its holdings in Collegium Pharmaceutical by 0.8% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 574,080 shares of the specialty pharmaceutical company’s stock worth $17,136,000 after acquiring an additional 4,513 shares during the last quarter. Emerald Advisers LLC raised its stake in Collegium Pharmaceutical by 1.8% in the 1st quarter. Emerald Advisers LLC now owns 826,475 shares of the specialty pharmaceutical company’s stock valued at $24,670,000 after acquiring an additional 14,795 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock valued at $21,309,000 after purchasing an additional 109,655 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.